Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.26)
# 1,065
Out of 5,040 analysts
108
Total ratings
41.18%
Success rate
17.46%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAVA Cassava Sciences | Initiates: Buy | $8 | $3.70 | +116.22% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $2.22 | +2,872.97% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.41 | +2,826.83% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.70 | +529.63% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.82 | +504.40% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $79.25 | -36.91% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.42 | +1,097.18% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $3.93 | +5,497.96% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.70 | +723.53% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.03 | +3,200.49% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $10.20 | +321.57% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.36 | +144.57% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.34 | +459.70% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $5.64 | +165.96% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $12.43 | +68.95% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.34 | +499.37% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.72 | +5,461.74% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $4.89 | +922.49% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $5.81 | +1,862.13% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $7.97 | +2,409.41% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.76 | +158.62% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $28.14 | +42.15% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.60 | +2,212.50% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.71 | +376.90% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $11.54 | +567.24% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.74 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $37.63 | +32.87% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.19 | +535.84% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.15 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $7.74 | +235.92% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $186.42 | -84.98% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.41 | +15,611.65% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $11.34 | +85.19% | 2 | Jul 12, 2017 |
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $3.70
Upside: +116.22%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $2.22
Upside: +2,872.97%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.41
Upside: +2,826.83%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.70
Upside: +529.63%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.82
Upside: +504.40%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $79.25
Upside: -36.91%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.42
Upside: +1,097.18%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $3.93
Upside: +5,497.96%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.70
Upside: +723.53%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.03
Upside: +3,200.49%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $10.20
Upside: +321.57%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $7.36
Upside: +144.57%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.34
Upside: +459.70%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $5.64
Upside: +165.96%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $12.43
Upside: +68.95%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.34
Upside: +499.37%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.72
Upside: +5,461.74%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $4.89
Upside: +922.49%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $5.81
Upside: +1,862.13%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $7.97
Upside: +2,409.41%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.76
Upside: +158.62%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $28.14
Upside: +42.15%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.60
Upside: +2,212.50%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.71
Upside: +376.90%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $11.54
Upside: +567.24%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.74
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $37.63
Upside: +32.87%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.19
Upside: +535.84%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.15
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $7.74
Upside: +235.92%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $186.42
Upside: -84.98%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.41
Upside: +15,611.65%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $11.34
Upside: +85.19%